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Abstract: Pyranoxanthones 6-8 were obtained by dehydrogenation of the respective 
dihydropyranoxanthones 3-5 with DDQ in dry dioxane. Two prenylated xanthones 10,11 
were obtained from the reaction of 1-hydroxyxanthone (9) with prenyl bromide in alkaline 
medium, or by condensation of xanthone 9 with isoprene in the presence of 
orthophosphoric acid. The structural elucidation of the two new compounds 6,11, as well 
as an update of data for the already described prenylated derivatives 7,8,10 were 
accomplished by IR, UV, HRMS and NMR (1H, 13C, HSQC and HMBC) techniques. The 
effect of the prenylated xanthone derivatives on the in vitro growth of human tumor cell 
lines MCF-7 (breast adenocarcinoma) and NCI-H460 (non-small cell lung cancer) is also 
reported. Compounds 10 and 11 have been found to exhibit a moderate growth inhibitory 
activity against the MCF-7 cell line. 
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1. Introduction  
Many naturally occurring xanthones and their prenylated derivatives are found to exhibit significant 
biological and pharmacological properties, such as antibacterial, antifungal and antitumor activities and 
it can be inferred that the presence of prenyl groups can be associated with an improvement of potency 
and selectivity for some of these properties [1,2]. As a large number of biologically active xanthone 
derivatives with pyran and dihydropyran rings are commonly found in Nature, we were interested in 
obtaining this type of compounds to evaluate their antitumor activity. For this purpose, molecular 
modifications of the hit compounds, 1,3-dihydroxy-2-methylxanthone (1) and 1,3-dihydroxyxanthone 
(2) (Figure 1) were carried out [3].  
Figure 1. Structures of the xanthone building blocks 1-5, 9 and prenylated derivatives 6-8, 
10 and 11 (the numbering used refers to the NMR assignments). 
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Prenylation of xanthones 1 and 2 with prenyl bromide, followed by cyclisation of the respective 
monoprenylated products furnished dihydropyranoxanthones 3-5 [3] (Figure 1), which were evaluated 
for their effects on the in vitro growth of three human tumour cell lines (MCF-7, NCI-H460 and  
SF-268). These compounds were found to be more selective, showing their growth inhibitory effects 
only against the breast cancer MCF-7 cells when compared with their building blocks, respectively 1 
and 2 [3]. 
The fact that naturally occurring pyranoxanthones are more active than dihydropyranoxanthones in 
many biological activity assays [1] has led us to resort to a rigidification strategy to improve the 
antitumor activity of the xanthone derivatives. Thus, unsaturation strategy was applied to the 
dihydropyran ring of dihydropyranoxanthones 3-5 to give pyranoxanthones 6-8, respectively  
(Figure 1). 
The second approach is to introduce the prenyl side chain to the xanthone nucleus, using a  
C-prenylation strategy. Thus, two C-prenylated derivatives, 10 and 11 were synthesized by prenylation 
of xanthone 9 (Figure 1). Though C-prenylated derivatives are not as common in nature as the  
O-prenylated analogues, they show very interesting properties [1]. Based on this observation, xanthone 
9 (Figure 1) was submitted to a C-prenylation strategy to furnish compounds 10 and 11. 
The xanthone derivatives 6-8, 10 and 11, were then evaluated for their capacity to inhibit the in 
vitro growth of MCF-7 (breast adenocarcinoma) and NCI-H460 (non-small cell lung cancer) cells, and 
their effects were compared with those of their building blocks [3,4]. 
2. Results and Discussion  
2.1. Synthesis of prenylated derivatives  
Pyranoxanthones 6-8 were obtained by dehydrogenation of the respective dihydropyranoxanthones 
3-5 with DDQ in refluxing dry dioxane [5]. While dihydropyranoxanthone 3 gave pyranoxanthone 6, 
dihydropyranoxanthone 4 afforded pyranoxanthone 7 (Scheme 1a) and dihydropyranoxanthone 5 gave 
pyranoxanthone 8 (Scheme 1b) in 67, 41 and 25% yield, respectively. 
Scheme 1. Synthesis of pyranoxanthones 6-8.  a). Synthesis of pyranoxanthones 6 and 7; 
b). Synthesis of pyranoxanthone 8. 
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Of these, pyranoxanthone 6, containing a methyl group at C-2 was formed with the highest yield 
(67%). It can be also observed that the angular pyranoxanthone 7 was obtained in higher yield than the 
linear counterpart 8. Prenylation of 1-hydroxyxanthone (9), either with prenyl bromide or isoprene, 
gave 1,1-dimethylallyl- or 3,3-dimethylallyl-derivatives 10 and 11, respectively, in low yields and 
after long reaction times. Xanthone 10 was obtained by the reaction of 1-hydroxyxanthone (9) with 
prenyl bromide, in alkaline medium and refluxing N,N-dimethylformamide [6] (DMF) (Scheme 2). 
Scheme 2. Synthesis of prenylated xanthones 10 and 11. 
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Mechanistically, the formation of xanthone 10 by the described method, can be postulated to occur 
by prenylation at 1-OH of xanthone 9 with subsequent ortho Claisen rearrangement of the prenyl 
group to give the 1,1-dimethylallyl substituent on C-2 of the xanthonic scaffold [7]. 
The prenylated derivative 11 was obtained by condensation of 1-hydroxyxanthone (9) with 
isoprene, in the presence of catalytic amounts of orthophosphoric acid [8] (Scheme 2). The acid-
catalysed condensation of isoprene with the phenol moiety of the xanthonic scaffold may be regarded 
as the chemical equivalent of the proposed biogenetic pathways [8]. 
2.2. Structural elucidation of the prenylated xanthones 
The structures of compounds 6-8 and 10, 11 were established by IR, UV, HRMS and NMR (1H-, 
13C-, HSQC and HMBC) techniques, while the spectroscopic data of compounds 1-5 and 9 are in 
agreement with those reported in the literature [3,9-12]. Although the spectroscopic data of 
pyranoxanthones 7 and 8, as well as of prenylated xanthone 10 have been previously described  
[7,13-14], here we provide an updated and complete structure elucidation of these compounds.  
The EI-HRMS of compound 6 gave the accurate molecular mass at 308.1049 and the corresponding 
molecular formula C19H16O4, indicating that there were two hydrogen atoms less than in its 
dihydropyranoxanthone precursor 3. The 1H-NMR spectrum of compound 6 was very similar to that of 
compound 3, except for the two doublets of the olefinic protons at δH 5.62 (J = 10.0 Hz) and δH 6.86  
(J = 10.0 Hz), instead of the triplets of the protons of two methylene groups at δH 1.88 (J = 6.8 Hz) and 
δH 2.89 (J = 6.8 Hz) of the dihydropyran ring [3]. The protons of the geminal methyl groups of the 
pyran ring in compound 6 appeared as a singlet at δH 1.50. The 13C-NMR spectrum of compound 6 was 
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also similar to that of dihydropyranoxanthone 3 [3], except for the substitution of the two methylene 
carbons at δC 16.4 and 31.7 with the two olefinic carbon signals at δC 115.3 and δC 126.8.  
In turn, the EI-HRMS of compound 7 indicated the accurate molecular mass at 294.0886, 
corresponding to the molecular formula C18H14O4. The 1H- and 13C-NMR spectra of compound 7 were 
very similar to those of compound 6, except for the presence of a singlet of the aromatic proton at C-2 
at δH 6.28 instead of the singlet of the methyl group at δH 2.12. As in compound 6, the presence of the 
pyran ring in compound 7 was confirmed by the two doublets of the olefinic protons at δH 5.62  
(J = 10.0 Hz) and δH 6.85 (J = 10.0 Hz) in the 1H-NMR spectrum which showed cross peaks with the 
olefinic carbons at δC 127.2 and δC 115.0, respectively in the HSQC spectrum.  
The EI-HRMS of compound 8 gave the accurate molecular mass at 294.0898 and the molecular 
formula C18H14O4. As expected, the 1H- and 13C-NMR spectra of compound 8 were similar to those of 
its dihydropyranoxanthone precursor 5 [3], except for the signals of the olefinic protons (δH 6.74, d,  
J = 10.0 Hz and δH 5.61, d, J = 10.0 Hz) and carbons (δC 115.4 and δC 127.6).  
Finally, the EI-HRMS of compounds 10 and 11 indicated their accurate molecular masses at 
280.1099 and 280.1096, respectively, and thus, a molecular formula C18H16O3 for both compounds. 
This molecular formula confirmed the prenylation of xanthone 9. In turn, the 1H-NMR spectra of 
compounds 10 and 11 showed, besides, the proton signals corresponding to the non substituted 
aromatic ring of the xanthone nucleus, the signals of another two ortho coupled aromatic protons  
(δH 6.88, d, J = 8.8 Hz; δH 7.64, d, J = 8.8 Hz and δH 6.76, d, J = 8.4 Hz; δH 7.46, d, J = 8.4 Hz) and  
1-OH (δH 13.47, s and δH 12.56, s). The presence of these two ortho coupled aromatic protons 
indicated that the prenylation occurred at C-2. That the side chain of compound 10 was 2-methylbut-3-
en-2-yl was confirmed by the signals of the protons of the vinyl group at δH 5.07, dd (J = 17.0, 1.2 Hz), 
δH 5.02, dd (J = 11.0, 1.2 Hz) and δH 6.28, dd (J = 17.0, 11.0 Hz) and the methyl groups at δH 1.55, s, 
respectively. This was corroborated by the correlation between the proton signal at δH 6.28, dd  
(J = 17.0, 11.0 Hz, H-2’) and the carbon signal at δC 128.9 (C-2). On the other hand, the 3-methylbut-
2-enyl side chain of compound 11 was established by the presence of the signals of the allylic proton 
at δH 5.33, t  (J = 7.4 Hz), the methyl protons at δH 1.76, s and δH 1.81, s and the methylene protons at 
δH 3.53, d (J = 7.4 Hz). The HMBC spectrum of compound 11 also showed the correlation between the 
signal of the methylene protons (δH 3.53, d) and the signal of C-1 at δC 160.0. 
Figure 2. Main connectivities found in the HMBC of prenylated xanthones 6-8, 10 and 11. 
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2.3. Biological Activity studies 
Though the number of compounds prepared was small, some basic structure-activity relationship 
trends can be observed. When the effects of the prenylated xanthones 6-8 on the growth of MCF-7 
cells are compared with those of their respective xanthonic building blocks 3-5, it was found that the 
presence of the unsaturation in the pyran ring was associated with a loss of inhibitory activity against 
MCF-7 (Table 1). It can be presumed that the lack of activity of compounds 6 and 8 could be a 
consequence of the rigidification of the dihydropyran ring. On the other hand, C-prenylation of the 
inactive xanthone 9 [4] was found to be associated with the growth of the inhibitory effect against 
MCF-7 of the prenylated derivatives 10 and 11 (Table 1). The introduction of the lipophilic prenyl 
group in C-2 of the xanthonic scaffold is probably the reason for the appearance of this activity for 
xanthones 10 and 11.   
 
Table 1. Effect of xanthone derivatives 1-11 on the growth of human tumor cell lines. 
Compound 
GI50 (µM) 
MCF-7 NCI-H460 SF-268 
1a 21.9 ± 0.4 20.6 ± 0.9 33.4 ± 0.2 
2a 50.8 ± 2.2 37.9 ± 2.9 61.4 ± 5.2 
3a 18.4 ± 1.9 >160 >160 
4a >160 >160 >160 
5a 88.6 ± 12.9 >160 >160 
6 >150b >150b ND 
7 >150 >150b ND 
8 >150b >150b ND 
9a >200 ND ND 
10 55b >150b ND 
11 88b ND ND 
Results are given in concentrations that were able to cause 50% of cell growth inhibition 
(GI50) after a continuous exposure of 48h and represent means of ±SEM of 3 independent 
experiments performed in duplicate and carry out independently. aResults published 
elsewhere [3,4]. bResults of one or two experiments performed in duplicate. Doxorubicin 
was used as positive control, GI50: MCF-7 = 42.8±8.2 nM; NCI-H460 = 94.0±8.7 nM; 
SF-268 = 93.0±7.0 nM. ND = not determined.
 
3. Experimental  
3.1. General 
Purification of compounds were performed by flash chromatography using Merck silica gel 60 
(0.040-0.063 mm) and preparative thin layer chromatography (TLC) using Merck silica gel 60 (GF254) 
plates. Reactions were monitored by TLC. Melting points were obtained in a Köfler microscope and 
are uncorrected. IR spectra were measured on an ATI Mattson Genesis series FTIR (software: 
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WinFirst v. 2.10) spectrophotometer in KBr microplates (cm-1). UV spectra were taken in ethanol [15] 
and were recorded on a Varian CARY 100 spectrophotometer: λmax in nm (software: Cary Win UV v. 
3.0). 1H and 13C NMR spectra were taken in CDCl3 at room temperature, on a Bruker Avance  
300 instrument. Chemical shifts are expressed in δ (ppm) values relative to tetramethylsilane (TMS) as 
an internal reference. 1H-NMR spectra were measured at 300.13 MHz and assignment abbreviations 
are the following: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets (dd), 
and double doublet of doublets (ddd). 13C-NMR spectra were measured at 75.47 MHz. 13C-NMR 
assignments were made by 2D HSQC and HMBC experiments (long-range C, H coupling constants 
were optimized to 7 Hz). HRMS spectra were recorded as EI (electronic impact) mode on a VG 
Autospec M spectrometer (m/z) at CACTI, Vigo, Spain. Prenyl bromide, Isoprene and DDQ were 
purchased from Sigma Aldrich. Compounds 1-5 and 9 were obtained and characterized according to 
the described procedures [3,9-12]. The following materials were synthesized and purified by the 
described procedures. 
3.2. General Procedure for the Synthesis of Pyranoxanthones 6-8 
To a solution of dihydropyranoxanthones 3-5 (0.06 mmol) in dry dioxane (10 mL) was added DDQ 
(0.12 mmol) and the reaction mixture was refluxed (100ºC) for 9-18 h. After cooling, the precipitate 
was filtered off and the filtrate evaporated. The crude product was purified by preparative TLC (SiO2; 
hexane/EtOAc 95:5 or light petroleum/CHCl3 5:5). Compounds 6, 7 [13] and 8 [14] were identified by 
their spectroscopic and analytical data. 
 
6-Hydroxy-3,3,5-trimethylpyrano[2,3-c]xanthen-7(3H)-one (6): The compound was obtained (67%) as 
yellow solid; m.p. 196-198ºC (EtOH); λmax (ε): 327, 273, 250 (6821, 25216, 22253); (EtOH + NaOH): 
426, 296, 217 (3056, 30278, 95370); (EtOH + AlCl3): 330, 275, 235 (6481, 24753, 17685); νmax (KBr): 
3431, 2959, 2917, 1644, 1606, 1564, 1471, 1431, 1320, 1145, 1108, 742 cm-1; 1H-NMR: δ =13.22 (s, 
1H, 1-OH), 8.25 (dd, 1H, J = 8.0, 1.6 Hz, 8-H), 7.70 (ddd, 1H, J = 8.4, 7.1, 1.6 Hz, 6-H), 7.44 (d, 1H, 
J = 8.4 Hz, 5-H), 7.36 (dd, 1H, J = 8.0, 7.1 Hz, 7-H), 6.86 (d, 1H, J = 10.0 Hz, 4’-H), 5.62 (d, 1H, 
J=10.0 Hz, 5’-H), 2.12 (s, 3H, 2-CH3), 1.50 (s, 6H, 6’-CH3) ppm; 13C-NMR: δ =180.8 (C-9), 160.5 (C-
1), 158.8 (C-3), 155.8 (C-10a), 149.8 (C-4a), 134.7 (C-6), 126.8 (C-5’), 125.9 (C-8), 123.8 (C-7), 
120.6 (C-8a), 117.5 (C-5), 115.3 (C-4’), 107.8 (C-2), 103.1 (C-9a), 100.5 (C-4), 78.0 (C-6’), 28.4 (6’-
CH3, 2C), 7.0 (2-CH3) ppm; EI-MS m/z (%): 308 (6, M+.), 293 (100), 267 (4), 149 (5), 137 (4), 121 (4), 
109 (5), 95 (6), 81 (11), 69 (12); EI-HR-MS m/z: Anal. Calc. for C19H16O4: 308.1049; found: 
308.1049. 
 
6-Hydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (7): The compound was obtained (41%) as 
yellow crystals; m.p. 164-168ºC (Acetone); λmax (ε): 271, 244, 201 (8471, 7588, 5603); (EtOH + 
NaOH): 293, 216 (9103, 45176); (EtOH + AlCl3): 335, 285, 228, 201 (2838, 9412, 6941, 6147); νmax 
(KBr): 3432, 2956, 2921, 2853, 1650, 1596, 1465, 1279, 1142, 1102, 1073, 804, 749 cm-1; 1H-NMR: 
δ =12.97 (s, 1H, 1-OH), 8.25 (d, 1H, J = 7.8 Hz, 8-H), 7.72 (dd, 1H, J = 8.4, 7.4 Hz, 6-H), 7.46 (d, 1H, 
J = 8.4 Hz, 5-H), 7.38 (dd, 1H, J = 7.8, 7.4 Hz, 7-H), 6.85 (d, 1H, J = 10.0 Hz, 4’-H), 6.28 (s, 1H, 2-
H), 5.62 (d, 1H, J=10.0 Hz, 5’-H), 1.49 (s, 6H, 6’-CH3) ppm; 13C-NMR: δ =180.9 (C-9), 163.2 (C-1), 
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161.0 (C-4a), 155.8 (C-10a), 151.8 (C-3), 135.0 (C-6), 127.2 (C-5’), 125.9 (C-8), 124.1 (C-7), 120.6 
(C-8a), 117.6 (C-5), 115.0 (C-4’), 103.8 (C-9a), 101.1 (C-4), 99.4 (C-2), 78.3 (C-6’), 28.3 (6’-CH3, 
2C) ppm; EI-MS m/z (%): 294 (2, M+.), 279 (22), 183 (74), 181 (78), 171 (60), 169 (66), 163 (100), 
149 (20), 145 (25), 117 (40), 115 (37), 104 (30), 103 (46), 91 (35), 90 (50), 89 (53), 77 (26); EI-HR-
MS m/z: Anal. Calc. for C18H14O4: 294.0892; found: 294.0886. 
 
5-Hydroxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (8): The compound was obtained (25%) as 
yellow crystals; m.p. 170-173ºC (Acetone); λmax (ε): 289, 237, 201 (17059, 14676, 11853); (EtOH + 
NaOH): 405, 309, 215 (1647, 14471, 88324); (EtOH + AlCl3): 293, 237, 201 (16471, 14765, 13324); 
νmax (KBr): 3410, 2963, 2921, 2855, 1646, 1609, 1567, 1453, 1301, 1212, 1139, 1081, 749 cm-1; 1H-
NMR: δ =13.17 (s, 1H, 1-OH), 8.24 (dd, 1H, J = 8.0, 1.6 Hz, 8-H), 7.70 (ddd, 1H, J = 8.6, 7.1, 1.6 Hz, 
6-H), 7.43 (d, 1H, J = 8.6 Hz, 5-H), 7.37 (dd, 1H, J = 8.0, 7.1 Hz, 7-H), 6.74 (d, 1H, J = 10.0 Hz, 4’-
H), 6.36 (s, 1H, 4-H), 5.61 (d, 1H, J=10.0 Hz, 5’-H), 1.49 (s, 6H, 6’-CH3) ppm; 13C-NMR: δ =180.8 
(C-9), 160.9 (C-3), 157.7 (C-1), 157.1 (C-4a), 155.9 (C-10a), 134.9 (C-6), 127.6 (C-5’), 125.8 (C-8), 
124.0 (C-7), 120.5 (C-8a), 117.6 (C-5), 115.4 (C-4’), 107.1 (C-4), 104.6 (C-2), 103.8 (C-9a), 78.3 (C-
6’), 28.4 (6’-CH3, 2C) ppm; EI-MS m/z (%): 294 (9, M+.), 279 (100), 69 (7); EI-HR-MS m/z: Anal. 
Calc. for C18H14O4: 294.0892; found: 294.0898. 
3.3. Synthesis of Prenylated Xanthone 10 
A mixture of 1-hydroxyxanthone (9) (0.10 g; 0.47 mmol), prenyl bromide (110 μL; 0.95 mmol) and 
anhydrous K2CO3 (0.22 g, 1.58 mmol) in dry DMF (7 mL), was refluxed at 150ºC for 24 h. After 
cooling, the solid was filtered and the solvent removed under reduced pressure, affording the crude 
product that was purified by flash chromatography (SiO2; Hexane/EtOAc 95:5) and by preparative 
TLC (SiO2; Hexane/CHCl3 9:1). The product, 1-hydroxy-2-(2-methylbut-3-en-2-yl)-9H-xanthen-9-one 
(10) [7] was obtained in 6% yield as yellow crystals, and identified by spectroscopic and analytical 
data; m.p. 99-102ºC (acetone); λmax (ε): 281, 258, 230, 203 (2511, 10196, 9453, 6858); (EtOH + 
NaOH): 426, 309, 216 (1641, 3815, 43184); (EtOH + AlCl3): 259, 231, 206 (7475, 9341, 6466); νmax 
(KBr): 3432, 2954, 2919, 2858, 1632, 1608, 1462, 1433, 1374, 1285, 1213, 1057, 752 cm-1; 1H-NMR: 
δ =13.47 (s, 1H, 1-OH), 8.29 (dd, 1H, J = 8.0, 1.6 Hz, 8-H), 7.74 (ddd, 1H, J = 8.7, 7.0, 1.6 Hz, 6-H), 
7.64 (d, 1H, J = 8.8 Hz, 3-H), 7.45 (d, 1H, J = 8.7 Hz, 5-H), 7.38 (dd, 1H, J = 8.0, 7.0 Hz, 7-H), 6.88 
(d, 1H, J = 8.8 Hz, 4-H), 6.28 (dd, 1H, J = 17.0, 11.0 Hz, 2’-H), 5.07 (dd, 1H, J=17.0, 1.2 Hz, 3’-H), 
5.02 (dd, 1H, J=11.0, 1.2 Hz, 3’-H), 1.55 (s, 6H, 1’-CH3) ppm; 13C-NMR: δ =182.9 (C-9), 160.5 (C-
1), 156.1 (C-10a), 154.8 (C-4a), 147.0 (C-2’), 135.4 (C-6), 135.0 (C-3), 128.9 (C-2), 126.0 (C-8), 
123.8 (C-7), 120.5 (C-8a), 117.7 (C-5), 110.6 (C-3’), 108.8 (C-9a), 105.6 (C-4), 40.3 (C-1’), 26.7 (1’-
CH3, 2C) ppm; EI-MS m/z (%): 280 (20, M+.), 265 (100), 251 (17), 250 (16), 239 (16), 237 (20), 225 
(35), 69 (11); EI-HR-MS m/z: Anal. Calc. for C18H16O3: 280.1100; found: 280.1099. 
3.4. Synthesis of prenylated xanthone 11 
A solution of isoprene (200 μL; 2.00 mmol) in xylene (1 mL) was added to a stirred mixture of 1-
hydroxyxanthone (9, 0.20 mg; 0.96 mmol), orthophosphoric acid (85%, 1 mL) and xylene (4 mL), with 
constant stirring at 31ºC during 2 h. The mixture was stirred for a further 28 h and then neutralised 
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with hydrogen carbonate solution (5%). The mixture thus obtained, was extracted with diethyl ether. 
The extract was washed with water, dried (Na2SO4) and the solvent evaporated under reduced 
pressure. The crude product thus obtained was purified by flash chromatography (SiO2; 
Hexane/EtOAc 98:2) and preparative TLC (SiO2; EP/Et2O 9:1). 1-Hydroxy-2-(3-methylbut-2-enyl)-
9H-xanthen-9-one (11) was identified by its spectroscopic and analytical data. Yield: 4%, as yellow 
crystals; m.p. 68-71ºC (acetone); λmax (ε): 368, 300, 257, 232, 203 (3240, 5526, 23689, 24109, 18794); 
(EtOH + NaOH): 416, 308, 265, 217 (4600, 9257, 16157, 49130); (EtOH + AlCl3): 445, 316, 275, 231, 
205 (3394, 7798, 21837, 26452, 20084); νmax (KBr): 3448, 2963, 2917, 2853, 1642, 1604, 1472, 1369, 
1279, 1227, 763 cm-1; 1H-NMR: δ =12.56 (s, 1H, 1-OH), 8.29 (dd, 1H, J = 8.0, 1.6 Hz, 8-H), 7.76 
(ddd, 1H, J = 8.4, 7.1, 1.6 Hz, 6-H), 7.51 (d, 1H, J = 8.4 Hz, 5-H), 7.46 (d, 1H, J = 8.4 Hz, 3-H), 7.40 
(dd, 1H, J = 8.0, 7.1 Hz, 7-H), 6.76 (d, 1H, J = 8.4 Hz, 4-H), 5.33 (t, 1H, J = 7.4 Hz, 2’-H), 3.53 (d, 
2H, J=7.4 Hz, 1’-H), 1.81 and 1.76 (2s, 2×3H, 3’-CH3) ppm; 13C-NMR: δ =182.6 (C-9), 160.0 (C-1), 
156.1 (C-10a), 153.4 (C-4a), 137.0 (C-3), 135.4 (C-6), 133.3 (C-3’), 126.0 (C-8), 124.0 (C-7), 121.7 
(C-2’), 120.5 (C-8a), 119.3 (C-2), 117.9 (C-5), 110.0 (C-4), 108.9 (C-9a), 27.6 (C-1’), 25.8 and 17.9 
(3’-CH3, 2C) ppm; EI-MS m/z (%): 280 (15, M+.), 265 (33), 225 (12), 149 (11), 137 (18), 121 (18), 
109 (12), 107 (12), 95 (26), 81 (69), 69 (100); EI-HR-MS m/z: Anal. Calc. for C18H16O3: 280.1100; 
found: 280.1096. 
3.5. Tumor cell growth assay  
Stock solutions of compounds 6-8, 10 and 11 and doxorubicin were prepared in DMSO (Sigma 
Chemical Co) and stored at –20 ºC. The frozen samples were freshly diluted with culture medium just 
prior the assays. Final concentrations of DMSO (0.25%) did not interfere with the growth of cell lines.  
The human tumor cell lines MCF-7 (breast adenocarcinoma) and NCI-H460 (non-small cell lung 
cancer) were used. Cells growing as monolayer, were routinely maintained in RPMI-1640 medium 
(Gibco BRL) supplemented with 5% heat-inactivated fetal bovine serum (Gibco BRL), 2 mM 
glutamine (Sigma Chemical Co.), penicillin 100 U/mL and 100 μg/mL streptomycin (Gibco BRL), at 
37 ºC in an humidified atmosphere containing 5% CO2. The optimal plating density of each cell line, 
that ensure exponential growth throughout all the experimental period was respectively 1.5 × 105 
cells/ml to MCF-7 and 7.5 × 104 cells/ml for NCI-H460.  
The effects of compounds on the growth of the human tumor cell lines were evaluated according to 
the procedure adopted by the National Cancer Institute (NCI, USA) for the “In vitro Anticancer Drug 
Discovery Screen” that uses the protein-binding dye sulforhodamine B (SRB) (Sigma Chemical Co.) 
to assess cell growth [16,17]. Briefly, exponentially growing cells were exposed for 48 h to five serial 
concentrations (1:2 or 1:3 dilution) of each compound, starting from a maximum concentration of  
150 μM. Following this exposure period adherent cells were fixed in situ with 50% TCA, washed with 
distillate water and stained with 0.4% SRB solubilized in 1% acetic acid. The bound stain was 
solubilized and the absorbance was measured at 492 nm in a microplate reader (Bio-tek Instruments 
Inc., PowerWave XS, Winooski, USA). For each cell line a dose-response curve was obtained and the 
growth inhibition of 50% (GI50), corresponding to the concentration of compound that inhibited 50% 
of the net cell growth, was determined as described elsewhere [16]. Doxorubicin used as a positive 
control, was tested in the same manner. Moreover the effect of the vehicle solvent (DMSO) on the 
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growth of these cell lines was evaluated in all experiments by exposing untreated control cells to the 
maximum concentration (0.25%) of DMSO used in each assay. 
4. Conclusions  
In contrast to their dihydropyranoxanthone precursors 3-5, the pyranoxanthones 6-8 did not exhibit 
growth inhibitory effect against the breast adenocarcinoma MCF-7 cells. On the other hand, C-
prenylation of the inactive hydroxyxanthone 9, led to prenylated derivatives 10 and 11 which exhibited 
moderate growth inhibitory activity against the MCF-cells. From these results, we can conclude that 
introduction of an unsaturation on the extra ring was not effective in improving the biological activity 
of these compounds. On the contrary, the introduction of the prenyl side chain on an appropriate 
position of the xanthonic scaffold was found to improve the antitumor activity of compounds 10 and 
11. The increase of the lipophilicity of the molecule and/or an extra molecular motif to interact with 
biological targets furnished by the prenyl group can be a key to explain the improvement this activity. 
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